{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-21-000213","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2021-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.243993+00:00","generated_at":"2026-06-28T18:11:57.878683+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lilly Q3 revenue up 18% to $6.77B; non-GAAP EPS $1.94 (+38%); pipeline advances with tirzepatide, donanemab","bullets":["Q3 revenue $6.773B (+18% YoY); GAAP EPS $1.22 (-8%), non-GAAP EPS $1.94 (+38%).","Key growth products (Trulicity +45%, Verzenio +43%) drove 17pp of growth; COVID-19 antibody revenue $423.5M.","Submitted tirzepatide NDA for type 2 diabetes with priority review voucher; initiated rolling submission for donanemab in early Alzheimer's.","FDA approved Verzenio for high-risk early breast cancer and Jardiance for HFrEF; positive Phase 3 for lebrikizumab in atopic dermatitis.","Repurchased higher-cost debt ($405.2M charge); issued €600M sustainability bond."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-21-000213","json":"https://secwatch.observer/filing/0000059478-21-000213.json","markdown":"https://secwatch.observer/filing/0000059478-21-000213.md","text":"https://secwatch.observer/filing/0000059478-21-000213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947821000213/0000059478-21-000213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947821000213/lly-20211026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T18:11:57.878683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}